Cytoplasmic sequestration of wild-type p53 in a patient with therapy-related resistant AML: First report

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 1148-1150

  Prokocimer, Miron ^a,c   Peller, Shoshana ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

AML; P53 cytoplasmic sequestration; Therapy resistance

Indexed keywords

CD11B ANTIGEN; CD131 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN KAPPA CHAIN; MELPHALAN; MITOXANTRONE; PREDNISONE; PROTEIN P53; ANTINEOPLASTIC AGENT; DNA; TP53 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CELL POPULATION; CYTOGENETICS; DISEASE DURATION; DISEASE SEVERITY; DNA SEQUENCE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EXON; FATIGUE; FEVER; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MONOSOMY; MULTIPLE MYELOMA; MYELOBLAST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; CYTOPLASM; DRUG RESISTANCE; ENZYME IMMUNOASSAY; GENETICS; METABOLISM;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOPLASM; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKEMIA, MYELOID, ACUTE; MALE; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866281272     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9916-x     Document Type: Article

References (12)

1. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer. 2004;4:106-17.
2. Green DR, Kroemer G. Cytoplasmic functions of the tumor suppressor p53. Nature. 2009;458:1127-30.
3. Tasdemir E, Maiuri MC, Galluzzi L, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biology. 2008;10:676-87.
4. Peller S, Yona R, Kopilova Y, et al. Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia. Genes Chromosomes Cancer. 1998;21:2-7.
5. Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood. 1994;84:2391-411.
6. Pedersen-Bjergaard J, Andersen MT, Andersen MK. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2007; 392-397.
7. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with complex aberrant karyotype. Leukemia. 2008;22:1539-41.
8. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP. Human p53 gene localized to short arm of chromosomee Nature. 1986;319:783-4.
9. O'Brate A, Giannakakou P. The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist Updat. 2003;6: 313-22.
10. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9:862-73.
11. Utama B, Shen YH, Mitchell BM, et al. Mechanisms for human cytomegalovirus-induced cytoplasmic p53 sequestration in endothelial cells. J Cell Sci. 2006;119:2457-67.
12. Bueso-Ramos CE, Yang Y, de Leon E, et al. The human MDM-2 oncogene is overexpressed in leukemias. Blood. 1993;82:2617-23.